Background Flow modulation is the newest endovascular technique for treatment of cerebral aneurysms.
Objective To investigate changes in aneurysm treatment practice patterns in the USA.
Methods From the 2007 to 2016, the National Inpatient Sample databases, hospital discharges associated with unruptured aneurysms (UA), and/or ruptured aneurysms (RA) having undergone surgical clipping (SC) and/or endovascular treatments (EVT) were identified using the International Classification of Diseases codes. Patient demographics, hospital characteristics, and clinical outcomes were reviewed. Five year subgroup analyses was performed for treatment differences.
Results A total of 39 282 hospital discharges were identified with a significant increase in EVT (UA: SC n=7847 vs EVT n=12 797, p<0.001; RA: SC n=8108 vs EVT n=10 530, p<0.001). Hospitals in the South demonstrated the most significant EVT use regardless of aneurysm status (UA: SC n=258.5±53.6 vs EVT n=480.7±155.8, p<0.001; RA: SC n=285.6±54.3 vs EVT n=393.3±102.9, p=0.003). From 2007 to 2011, there was no significant difference in the mean number of cases for the treatment modalities (UA: SC n=847.4±107.7 vs EVT n=11200.4±254.1, p=0.21; RA: SC n=949.4±52.8 vs EVT n=10540.4±219.6, p=0.85). Comparatively, from 2012 to 2016, significantly more UA and RA were treated endovascularly (UA: SC n=722.0±43.4 vs EVT n=14390.0±419.2, p<0.001; RA: SC n=672.2±61.4 vs EVT n=10510.6±330.2, p=0.02).
Conclusions As technological innovations continue to advance the neuroendovascular space, the standard of care for treatment of cerebral aneurysms is shifting further towards endovascular therapies over open surgical approaches in the USA.
- flow diverter
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @dralexandercoon, @drlimeilin
Contributors ASW collected and analyzed the data, drafted the original manuscript, and revised the paper. JKC critically reviewed the paper. GPC and ALC revised the paper. L-ML conceptualized and supervised the study, and revised the paper.
Funding This study was partially funded by Western University Summer Research Fellowship Award to ASW.
Competing interests GPC is a consultant/proctor for Stryker Neurovascular, MicroVention and Medtronic. ALC is a consultant/proctor for Stryker Neurovascular, Medtronic, and MicroVention, and share holder for InNeuroCo. L-ML is a consultant/proctor for Stryker Neurovascular and a consultant for MicroVention and Cerenovus.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.